Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

N6037

Sigma-Aldrich

Neridronate

≥97% (NMR), solid, bone resorption inhibitor

Synonym(s):

6-Amino-1-hydroxyhexylidene bisphosphonic acid, Neridronic acid, Nerixia

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C6H17NO7P2
CAS Number:
79778-41-9
Molecular Weight:
277.15
MDL number:
MFCD00866995
UNSPSC Code:
51111800
PubChem Substance ID:
24724553
NACRES:
NA.77

product name

Neridronate, ≥97% (NMR), solid

description

may contain <1% (w/w) inorganic salts

Quality Level

100

Assay

≥97% (NMR)

form

solid

color

white

solubility

H2O: >5 mg/mL

storage temp.

2-8°C

SMILES string

NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O

InChI

1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)

InChI key

PUUSSSIBPPTKTP-UHFFFAOYSA-N

Biochem/physiol Actions

Neridronate is a bone resorption inhibitor. It is used to treat Osteogenesis Imperfecta, an "orphan disease" characterized by a fragility of the bone enough to be named the "illness of bones of crystal".

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Evelina Maines et al.
Journal of bone and mineral metabolism, 30(4), 434-438 (2011-11-09)
Over recent years, several reports have been published on unusual cases of osteonecrosis of the jaw (ONJ) in adults using second- and third-generation nitrogen-containing bisphosphonates such as pamidronate, alendronate, risedronate and zoledronate, but no case has ever been reported either
Luigi Gennari et al.
Mini reviews in medicinal chemistry, 9(9), 1052-1063 (2009-08-20)
Paget's disease of bone is a focal skeletal disorder characterized by the formation of structurally abnormal bone, deformity and other complications leading to significant disability and bone pain. Recently, the availability of newer, more potent nitrogen-containing bisphosphonates has improved treatment
Davide Gatti et al.
Bone, 50(3), 739-742 (2011-12-20)
The benefits coming from long-term treatment of postmenopausal osteoporosis with bisphophonates are limited by a coupled decrease in bone formation. The objective of this study is to determine whether this decrease in bone formation is associated with changes in serum
Role of neridronate on MCF-7 estrogen dependent breast cancer model of bone metastasis: a preliminary study.
Vanessa Nicolin et al.
Investigational new drugs, 29(1), 189-191 (2009-10-03)
Ombretta Viapiana et al.
Rheumatology (Oxford, England), 53(1), 90-94 (2013-09-27)
The objective of this study was to evaluate if the anti-inflammatory properties of bisphosphonates and their effect on bone turnover could be useful in the treatment of AS. Sixty patients were consecutively assigned in a 1:1 ratio in a 6-month
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service